EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Lipofectamine-Mediated CRISPR-Cas9 Delivery Targeting the mecA Gene in Methicillin-Resistant Staphylococcus aureus: A Novel Approach to Reverse Antibiotic Resistance

Aamir Ajmal, Fasiha, Hafiza Kainat Gharsheen, Muhammad Amjad Ali, Rida Saleem, Muhammad Shahbaz Saleem, Muhammad Faizan Sajid, Amina Tariq, Amna Noor, Tahseen Siyal

Wah Academia Journal of Health and Nutrition · 30.06.2026 · 2 (2) · 27-35

DOI: 10.63954/bantev40 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Wah Academia Journal of Health and Nutrition, online erschienen am 30.06.2026. Verfasst von Aamir Ajmal und 9 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Healthcare-associated (HA) infections caused by methicillin-resistant Staphylococcus aureus (MRSA) continue to be a big problem worldwide. The mecA gene is responsible for the production of PBP2a which is responsible for the resistance to all beta-lactam antibiotics. There are currently very little alternative therapeutic options as the treatment is becoming limited. The advantage of CRISPR-Cas9 technology lies in the ability to target genes with precision, however, there are technical delivery challenges in the application of this technology in bacterial pathogens.

Objective

The aim of this study was to assess the efficacy of CRISPR-Cas9 delivery by liposomes with Lipofectamine and its ability to knock out the mecA gene in MRSA and make them susceptible to beta-lactam antibiotics.

Methods

MO of MRSA ATCC 43300 was electroporated with a Cas9-sgRNA RNP complex using Lipofectamine CRISPRMAX with a mecA-targeting guide sgRNA designed using CHOPCHOP. An antibacterial activity was determined (CFU, growth curves, biofilm), gene targeting (PCR, Sanger sequencing), resistance reversal (MIC, disk diffusion) and safety (MTT, hemolysis). All experiments were repeated three times (n=3), data presented as mean ± SD and analyzed by One Way Analysis of Variance (ANOVA) with Tukey's post hoc test (p

Zitieren

APA

Ajmal, A., Fasiha, Gharsheen, H. K., Ali, M. A., Saleem, R., Saleem, M. S., Sajid, M. F., Tariq, A., Noor, A., & Siyal, T. (2026). Lipofectamine-Mediated CRISPR-Cas9 Delivery Targeting the mecA Gene in Methicillin-Resistant Staphylococcus aureus: A Novel Approach to Reverse Antibiotic Resistance. Wah Academia Journal of Health and Nutrition, 2(2), 27-35. https://doi.org/10.63954/bantev40

Vancouver

Ajmal A, Fasiha, Gharsheen HK, Ali MA, Saleem R, Saleem MS, et al. Lipofectamine-Mediated CRISPR-Cas9 Delivery Targeting the mecA Gene in Methicillin-Resistant Staphylococcus aureus: A Novel Approach to Reverse Antibiotic Resistance. Wah Academia Journal of Health and Nutrition. 2026;2(2):27-35. doi:10.63954/bantev40

BibTeX
@article{Ajmal2026,
  author = {Ajmal, Aamir and Fasiha and Gharsheen, Hafiza Kainat and Ali, Muhammad Amjad and Saleem, Rida and Saleem, Muhammad Shahbaz and Sajid, Muhammad Faizan and Tariq, Amina and Noor, Amna and Siyal, Tahseen},
  title = {Lipofectamine-Mediated CRISPR-Cas9 Delivery Targeting the mecA Gene in Methicillin-Resistant Staphylococcus aureus: A Novel Approach to Reverse Antibiotic Resistance},
  journal = {Wah Academia Journal of Health and Nutrition},
  year = {2026},
  volume = {2},
  number = {2},
  pages = {27--35},
  doi = {10.63954/bantev40}
}
Kostenlos starten →